Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer

The objective of this study was to assess the efficacy and tolerability of YM155, a survivin suppressor, in combination with docetaxel, compared with docetaxel alone in patients with HER2-negative metastatic breast cancer. This phase II, multicenter, open-label, 2-arm study randomized patients (≥18 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemens, Michael R., Gladkov, Oleg A., Gartner, Elaina, Vladimirov, Vladimir, Crown, John, Steinberg, Joyce, Jie, Fei, Keating, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298663/
https://www.ncbi.nlm.nih.gov/pubmed/25547219
http://dx.doi.org/10.1007/s10549-014-3238-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298663/
https://www.ncbi.nlm.nih.gov/pubmed/25547219
http://dx.doi.org/10.1007/s10549-014-3238-6

Ejemplares similares